Board of Directors

The Board of Directors oversees the day-to-day running of our association and the Chairman of the Board is the highest representative of Asebio. The assembly held in December 2017 chose the candidacy with Jordi Martí (Ferrer Internacional) as chairman and Carlos Buesa (Oryzon Genomics), Carmen Eibe (Pharma Mar) and Daniel Ramón (Biopolis) as the three vice presidents. They will hold these offices until late 2019.

Jordi Martí
Chairman
Jordi Martí

Advisor to the pharmaceutical company Ferrer, Jordi Martí has already chaired Asebio's Board of Diretors in the period 2015-2017, as CEO of Celgene. He ls a long long experience in the biotech sector and has been the CEO of the Spanish subsidiary of Amgen between 2003 and 2012.

Carlos Buesa
1st Vice President
Carlos Buesa

CEO of the biotechnology company Oryzon Genomics, which he founded in 2000 after working for 15 years as a researcher at the University of Barcelona.

Carmen Eibe
2nd Vice President
Carmen Eibe

Director of Project Coordination and Institutional Relations at PharmaMar, whom she represents on the Asebio Board since 2014.

Daniel Ramón
3rd Vice President
Daniel Ramón

Daniel Ramon founded Biopolis in 2009 after working for more than 20 years as a professor at the Institute of Agrochemistry and Food Technology (IATA) in Valencia. Since the acquisition of Biopolis by Archer Daniels Midland Company (ADM), he is the R&D Director of the Bioactive Unit .

Dámaso Molero
Member of the Board
Dámaso Molero

General Director of 3P Biopharmaceuticals since 2007, Dámaso Molero has a long experience in pharmaceutical production, with more than 10 years as a plant manager in Shionogi

Miquel Angel Bonachera
Member of the Board
Miquel Ángel Bonachera

Biochemist and MBA by Esade, Bonachera has been CEO and CFO in AB-Biotics, a company specializing in probiotics that he founded together with Sergi Audivert in 2004.

Antonio Bañares
Member of the Board
Antonio Bañares

Director of Market Access and Governance at AbbVie since 2013. He had been previously Director of Health Management and Institutional Relations at Abbott Laboratories and General Director of the company's foundation.

Carles Domenech
Member of the Board
Carles Domenech

CEO and Vice President of Business Development and Licensing of Ability Pharma since 2009. At the same time, he has been a consultant for biotech projects of the investment company Kieretsu Forum Spain.

Santiago de Torres
Member of the Board
Santiago de Torres

Executive Chairman of the Board of Atrys Health, Torres, a physician specializing in Clinical Pharmacology, is also part of the board of various organizations with social purposes.

Soraya Gamonal
Member of the Board
Soraya Gamonal

Head of Innovation for Spain, Portugal and Latin America in Ayming, a company she joined in 2007 as a senior R&D consultant.

Richard Borreani
Member of the Board
Richard Borreani

Director of Agricultural Policies and Institutional Relations at Bayer Crop Science Iberia, the agro division of the multinational, which is the third largest company in the world in products for agriculture.

Enrique Castellón
Member of the Board
Enrique Castellón

Co-founder and president since 2001 of the investment company Cross Road Biotech, Castellón was Secretary of State for Health and Consumer Affairs (1996-2000), a position from which he promoted multiple projects of great relevance to the sector.

Eduard Valentí
Member of the Board
Eduard Valentí

Director of Regulatory Affairs and Head of Pharmaceutical Quality at Esteve, a company he joined as a researcher in 1988 and whose R&D department he led for more than 13 years.

Sin imagen
Member of the Board
Pending designation
Belén Barreiro
Member of the Board
Belén Barreiro

General Director of Ingenasa, a company specializing in biotechnology for the veterinary sector, which she joined in 1994 as marketing director.

Ana Polanco
Member of the Board
Ana Polanco

Director of Market Access & Corporate Affairs at Merck, she has extensive experience in market access at companies such as Novo Nordisk and Bristol-Myers Squibb.

Regina Revilla
Member of the Board
Regina Revilla

Director of External Relations of the pharma company MSD, Revilla has held various positions of responsibility in the Public Administration and chaired Asebio between 2011 and 2015.

Elena Rivas
Member of the Board
Elena Rivas

Responsible for Business Development at Nanoinmunotech since 2016, Rivas has extensive experience in the sector and has worked as a product manager and marketing director in several biotechnology start-ups.

Juan Cruz Cigudosa
Member of the Board
Juan Cruz Cigudosa

Co-founder and scientific director of NIMgenetics, Cruz is also President of the Spanish Association of Human Genetics (AEGH) and honorary professor of the Department of Biology of the Autonomous University of Madrid.

Andrés Ballesteros
Member of the Board
Andrés Ballesteros

Founding partner and CEO of Vivia Biotech, a company specializing in drug screening, which he joined after 10 years working as a lawyer in the United States.